移植前使用免疫检查点抑制剂对肝细胞癌移植后结局的影响:系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入91例移植前接受免疫检查点抑制剂(ICI)治疗的肝细胞癌患者,中位随访690.0天,移植后同种异体移植物排斥24例(26.4%)、HCC复发9例(9.9%)、死亡9例(9.9%)。年龄与ICI洗脱时间与排斥风险相关,中位洗脱94天时排斥概率≤20%;复发患者ICI周期数更少且符合米兰标准比例更低。
要点
- 91例移植前ICI治疗的HCC患者中,同种异体移植物排斥24例(26.4%)、复发9例(9.9%)、死亡9例(9.9%)。
- 年龄(每10年aHR 0.72)与ICI洗脱时间(每周aHR 0.92)与排斥风险相关。
- 复发患者中位ICI周期数少于无复发者(4.0 vs 8.0),符合米兰标准比例更低(16.7% vs 65.3%)。
核心结论
- 患者接受ICI治疗后的移植后结局可接受。
- 年龄和ICI洗脱时长与同种异体移植物排斥风险相关,3个月洗脱可能将其降至无ICI暴露患者的水平。
- ICI周期数和肿瘤负荷可能影响复发风险。
- 需要大型前瞻性研究证实这些关联。
研究设计与样本
- 系统综述与个体患者数据Meta分析,检索数据库纳入移植前接受ICI治疗的HCC病例,分析同种异体移植物排斥、HCC复发和总生存,并用Cox回归分析排斥危险因素。
- 共纳入91例符合条件的患者,中位(IQR)随访690.0(654.5)天。
主要发现
- 91例中同种异体移植物排斥24例(26.4%)、HCC复发9例(9.9%)、死亡9例(9.9%)。
- 年龄(每10年aHR 0.72,95%CI 0.53-0.99,p=0.044)和ICI洗脱时间(每周aHR 0.92,95%CI 0.86-0.99,p=0.022)与同种异体移植物排斥相关。
- 排斥概率≤20%的患者中位(IQR)洗脱期为94(196)天。
- 有无同种异体移植物排斥的病例总生存无差异(log-rank检验,p=0.2)。
- HCC复发者中位(IQR)ICI周期数少于无复发者(4.0[1.8] vs 8.0[9.0];p=0.025),且ICI后符合米兰标准比例更低(16.7% vs 65.3%,p=0.032)。
临床怎么用
- 作者认为,年龄和ICI洗脱时长与同种异体移植物排斥风险相关,3个月洗脱可能将排斥风险降至无ICI暴露患者的水平。
- 作者认为,ICI周期数和肿瘤负荷可能影响复发风险,但该观察需在更大规模前瞻性研究中进一步验证。
局限性
- 需要大型前瞻性研究证实这些关联。
- 该观察需在更大规模前瞻性研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatment with immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) prior to liver transplantation (LT) has been reported; however, ICIs may elevate the risk of allograft rejection and impact other clinical outcomes. This study aims to summarize the impact of ICI use on post-LT outcomes. METHODS: In this individual patient data meta-analysis, we searched databases to identify HCC cases treated with ICIs before LT, detailing allograft rejection, HCC recurrence, and overall survival. We performed Cox regression analysis to identify risk factors for allograft rejection. RESULTS: Among 91 eligible patients, with a median (IQR) follow-up of 690.0 (654.5) days, there were 24 (26.4%) allograft rejections, 9 (9.9%) HCC recurrences, and 9 (9.9%) deaths. Age (adjusted hazard ratio [aHR] per 10 years 0.72, 95% CI 0.53-0.99, p = 0.044) and ICI washout time (aHR per 1 week 0.92, 95% CI 0.86-0.99, p = 0.022) were associated with allograft rejection. The median (IQR) washout period for patients with ≤20% probability of allograft rejection was 94 (196) days. Overall survival did not differ between cases with and without allograft rejection (log-rank test, p = 0.2). Individuals with HCC recurrence had fewer median (IQR) ICI cycles than those without recurrence (4.0 [1.8] vs. 8.0 [9.0]; p = 0.025). The proportion of patients within Milan post-ICI was lower for those with recurrence vs. without (16.7% vs. 65.3%, p = 0.032). CONCLUSION: Patients have acceptable post-LT outcomes after ICI therapy. Age and ICI washout length relate to the allograft rejection risk, and a 3-month washout may reduce it to that of patients without ICI exposure. Number of ICI cycles and tumor burden may affect recurrence risk. Large prospective studies are necessary to confirm these associations. IMPACT AND IMPLICATIONS: This systematic review and individual patient data meta-analysis of 91 patients with hepatocellular carcinoma and immune checkpoint inhibitor use prior to liver transplantation suggest acceptable overall post-transplant outcomes. Older age and longer immune checkpoint inhibitor washout period have a significant inverse association with the risk of allograft rejection. A 3-month washout may reduce it to that of patients without immune checkpoint inhibitor exposure. Additionally, a higher number of immune checkpoint inhibitor cycles and tumor burden within Milan criteria at the completion of immunotherapy may predict a decreased risk of hepatocellular carcinoma recurrence, but this observation requires further validation in larger prospective studies.
引用
- Rezaee-Zavareh MS, Yeo YH, Wang T, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2024. PMID: 38996924. doi:10.1016/j.jhep.2024.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。